130 related articles for article (PubMed ID: 38677749)
21. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas.
Viñal D; Martinez D; Garcia-Cuesta JA; Gutierrez-Sainz L; Martinez-Recio S; Villamayor J; Martinez-Marin V; Gallego A; Ortiz-Cruz E; Mendiola M; Pozo-Kreilinger JJ; Berjon A; Belinchon B; Bernabeu D; Espinosa E; Feliu J; Redondo A
Clin Transl Oncol; 2020 Oct; 22(10):1849-1856. PubMed ID: 32125644
[TBL] [Abstract][Full Text] [Related]
22. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
23. The utility of inflammatory biomarkers in predicting overall survival and recurrence in skull base chordoma.
Hoppe M; Gersey ZC; Muthiah N; Abdallah HM; Plute T; Abou-Al-Shaar H; Wang EW; Snyderman CH; Zenonos GA; Gardner PA
Neurosurg Focus; 2024 May; 56(5):E16. PubMed ID: 38691858
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
[TBL] [Abstract][Full Text] [Related]
25. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Jiang C; Zhang S; Qiao K; Xiu Y; Yu X; Huang Y
Clin Breast Cancer; 2022 Jul; 22(5):424-438. PubMed ID: 35428593
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Grosso F; D'Ambrosio L; Zucchetti M; Ibrahim T; Tamberi S; Matteo C; Rulli E; Comandini D; Palmerini E; Baldi GG; DeCensi A; Bergaglio M; Marra D; Marchesi E; Siri G; D'Incalci M; Grignani G
Cancer; 2020 Nov; 126(21):4726-4734. PubMed ID: 32749681
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Xiong Y; Zhao N; Zheng Y; Wang J; Wei F; Ren X
Tumour Biol; 2017 Jun; 39(6):1010428317701639. PubMed ID: 28618954
[TBL] [Abstract][Full Text] [Related]
28. Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results.
Zhou DD; King D; Thomson K; Grimison P
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e526-e528. PubMed ID: 35297193
[No Abstract] [Full Text] [Related]
29. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
Jones RL; Maki RG; Patel SR; Wang G; McGowan TA; Shalaby WS; Knoblauch RE; von Mehren M; Demetri GD
Cancer; 2019 Dec; 125(24):4435-4441. PubMed ID: 31503332
[TBL] [Abstract][Full Text] [Related]
31. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Capacity of Systemic Inflammation Response Index, Neutrophil-to-Lymphocyte Ratio, Lymphocyte-to-Monocyte Ratio, and Platelet-to-Lymphocyte Ratio in Patients with Hypopharyngeal Squamous Cell Carcinoma.
Wang T; Lin H; Hsueh C; Lau HC; Zhou J; Gong H; Tao L; Zhou L; Wu C
ORL J Otorhinolaryngol Relat Spec; 2022; 84(6):453-463. PubMed ID: 35709701
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy.
Yang J; Xu H; Guo X; Zhang J; Ye X; Yang Y; Ma X
Sci Rep; 2018 Feb; 8(1):3044. PubMed ID: 29445100
[TBL] [Abstract][Full Text] [Related]
34. HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.
Moura DS; Mondaza-Hernandez JL; Sanchez-Bustos P; Peña-Chilet M; Cordero-Varela JA; Lopez-Alvarez M; Carrillo-Garcia J; Martin-Ruiz M; Romero-Gonzalez P; Renshaw-Calderon M; Ramos R; Marcilla D; Alvarez-Alegret R; Agra-Pujol C; Izquierdo F; Ortega-Medina L; Martin-Davila F; Hernandez-Leon CN; Romagosa C; Salgado MAV; Lavernia J; Bagué S; Mayodormo-Aranda E; Alvarez R; Valverde C; Martinez-Trufero J; Castilla-Ramirez C; Gutierrez A; Dopazo J; Hindi N; Garcia-Foncillas J; Martin-Broto J
Cell Mol Life Sci; 2024 May; 81(1):219. PubMed ID: 38758230
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
37. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
[TBL] [Abstract][Full Text] [Related]
38. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J;
Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
[TBL] [Abstract][Full Text] [Related]
40. Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Kawaguchi K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Hayashi N; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Cancer Diagn Progn; 2021; 1(4):303-308. PubMed ID: 35403143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
